Prenetics, a genetics and diagnostic health testing company, agreed to acquire a majority stake in ACT Genomics, a cancer solution provider, for $59m. "We are very excited in joining the Prenetics family. The investment and partnership of Prenetics into ACT will significantly broaden our horizon in terms of product offerings, business strategy and vision. Our team is ready to make meaningful contributions to the enlarged group with our technical expertise, as well as our first-hand clinical experience. The synergy and combined resources will enable us to provide more comprehensive solutions and better services to more patients and pharmaceutical companies in greater geographies," Hua Chien Chen, ACT CEO.